EP4076474A4 - Composition comprising 2'-fl and dfl for use in a method for reducing pain - Google Patents

Composition comprising 2'-fl and dfl for use in a method for reducing pain Download PDF

Info

Publication number
EP4076474A4
EP4076474A4 EP20895562.5A EP20895562A EP4076474A4 EP 4076474 A4 EP4076474 A4 EP 4076474A4 EP 20895562 A EP20895562 A EP 20895562A EP 4076474 A4 EP4076474 A4 EP 4076474A4
Authority
EP
European Patent Office
Prior art keywords
dfl
composition
reducing pain
pain
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20895562.5A
Other languages
German (de)
French (fr)
Other versions
EP4076474A1 (en
Inventor
Bruce Mcconnell
Louise Kristine VIGSNÆS
Gabriela Bergonzelli Degonda
Laurent Favre
Laurent Ferrier
Clara Lucia Garcia-Rodenas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycom AS
Original Assignee
Glycom AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/706,627 external-priority patent/US20200138838A1/en
Application filed by Glycom AS filed Critical Glycom AS
Publication of EP4076474A1 publication Critical patent/EP4076474A1/en
Publication of EP4076474A4 publication Critical patent/EP4076474A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
EP20895562.5A 2019-12-06 2020-12-07 Composition comprising 2'-fl and dfl for use in a method for reducing pain Pending EP4076474A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201901439 2019-12-06
US16/706,627 US20200138838A1 (en) 2014-10-29 2019-12-06 Composition comprising hmss/hmos and use thereof
PCT/IB2020/061578 WO2021111422A1 (en) 2019-12-06 2020-12-07 Composition comprising 2'-fl and dfl for use in a method for reducing pain

Publications (2)

Publication Number Publication Date
EP4076474A1 EP4076474A1 (en) 2022-10-26
EP4076474A4 true EP4076474A4 (en) 2024-02-28

Family

ID=76222486

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20895562.5A Pending EP4076474A4 (en) 2019-12-06 2020-12-07 Composition comprising 2'-fl and dfl for use in a method for reducing pain

Country Status (3)

Country Link
EP (1) EP4076474A4 (en)
BR (1) BR112022016589A2 (en)
WO (1) WO2021111422A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024042235A1 (en) * 2022-08-25 2024-02-29 Dsm Ip Assets B.V. Hybrid method for producing complex hmos

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180368460A1 (en) * 2015-12-15 2018-12-27 Glycom A/S MIXTURE OF HMOs
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception
US10946032B2 (en) * 2014-10-24 2021-03-16 Glycom A/S Mixtures of HMOs
WO2021110911A1 (en) * 2019-12-06 2021-06-10 Societe Des Produits Nestle S.A. Compositions for use in the reduction of pain and/or perception of pain in infants and young children
US20230338403A1 (en) * 2014-10-29 2023-10-26 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3335576A1 (en) * 2010-12-31 2018-06-20 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
CN103442696B (en) * 2011-02-04 2016-09-21 加利福尼亚大学董事会 Prevention or two sialic acid LNT (oligosaccharide). (DSLNT) or its variant, isomer, sum analogous to general Dedekind sum of suppression enteropathy
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
WO2017190755A1 (en) * 2016-05-05 2017-11-09 Glycom A/S Composition comprising hmos for use in the treatment of mast cell mediated visceral hypersensitivity and/or pain
US20200129534A1 (en) * 2017-04-07 2020-04-30 Children's Hospital Medical Center Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
WO2018207110A1 (en) * 2017-05-09 2018-11-15 Glycom A/S Synthetic composition for microbiota modulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10946032B2 (en) * 2014-10-24 2021-03-16 Glycom A/S Mixtures of HMOs
US20230338403A1 (en) * 2014-10-29 2023-10-26 Glycom A/S Composition comprising 2'-fl and dfl for use in a method for reducing pain
US20180368460A1 (en) * 2015-12-15 2018-12-27 Glycom A/S MIXTURE OF HMOs
WO2019123316A1 (en) * 2017-12-22 2019-06-27 Glycom A/S Composition comprising hmos for preventing or reducing nociception
WO2021110911A1 (en) * 2019-12-06 2021-06-10 Societe Des Produits Nestle S.A. Compositions for use in the reduction of pain and/or perception of pain in infants and young children

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADAMS CLIFFORD A ET AL: "The benefits of human milk oligosaccharides in adult nutrition", NUTRAFOODS, 1 January 2018 (2018-01-01), pages 169 - 173, XP055773392, Retrieved from the Internet <URL:http://jennewein-biotech.de/cms/assets/uploads/2018/11/ArticleNutrafoodsNov2018.pdf> [retrieved on 20210208], DOI: 10.17470/NF-018-1021-4 *
See also references of WO2021111422A1 *
VAN DEN ABBEELE P ET AL: "2'-Fucosyllactose alters the composition and activity of gut microbiota from formula-fed infants receiving complementary feeding in a validated intestinal model", JOURNAL OF FUNCTIONAL FOODS, ELSEVIER BV, NL, vol. 61, 2 August 2019 (2019-08-02), XP085765009, ISSN: 1756-4646, [retrieved on 20190802], DOI: 10.1016/J.JFF.2019.103484 *

Also Published As

Publication number Publication date
BR112022016589A2 (en) 2022-10-11
EP4076474A1 (en) 2022-10-26
WO2021111422A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
EP4060384A4 (en) Cloud-end&#34; architecture-based ppp-rtk enhancement method and system
EP3755805A4 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
EP4074832A4 (en) Method for creating new gene in organism and use thereof
EP4007326A4 (en) Method and device for activating 5g user
EP3709638C0 (en) System and method for projecting digital content onto user&#39;s facial surface
EP3950682A4 (en) Preparation method for amide compounds and use thereof in medical field
EP4059930A4 (en) Amide derivative and preparation method therefor and application thereof in medicine
EP4076474A4 (en) Composition comprising 2&#39;-fl and dfl for use in a method for reducing pain
EP4043550A4 (en) Composition for augmenting stemness and use thereof
EP3992194A4 (en) Benzodiazepine compound, preparation method therefor, and use thereof in medicine
EP3990115A4 (en) Methods and materials for treating huntington&#39;s disease
GB202306160D0 (en) Use and method
EP3896170A4 (en) Method for identifying 2&#39;-o-methylation modification in rna molecule, and application thereof
EP4096661A4 (en) Compounds and compositions for use in treating skin disorders
EP3986439A4 (en) Compositions and methods useful in treating brain diseases
GB202113683D0 (en) Use and method
EP4034083A4 (en) Lactic acid vaginal film and it&#39;s process
EP4054558A4 (en) Methods and compositions for type 2 diabetes therapy
EP4032611A4 (en) Composite material and use thereof in desulfurization
EP3954680A4 (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
EP3616723A4 (en) Method for treating myopia and application thereof in preparing drug
EP4061408A4 (en) Compositions and methods for use in type 1 diabetes
TWI851428B (en) Esg management system during the credit period and method thereof
EP4049725A4 (en) Combined use of biotin and thiamine in the treatment of huntington&#39;s disease
GB202406496D0 (en) Use, method and composition

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220826

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20240124BHEP

Ipc: A61K 31/702 20060101AFI20240124BHEP